Salarius Pharmaceuticals, Inc. Overview
Pro stress-test →Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company which engages in the development of treatments for cancers with high, unmet medical need. The company focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing, leveraging machine learning and artificial intelligence tools alongside synthesis techniques.
Strategic Profile
Pro stress-test →Salarius has undergone a significant strategic transformation through its merger with Decoy Therapeutics Inc. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company faces significant execution risk as a pre-revenue clinical-stage asset with early-stage pipeline programs.
Competitive Landscape
Pro stress-test →Salarius competes in the peptide-conjugate therapeutics and oncology drug development space against larger biopharmaceutical companies and specialized biotech firms developing targeted therapies. Competitors include larger oncology-focused companies (Celgene, Adaptive Biotechnologies) and smaller clinical-stage peers in targeted protein degradation and hematologic cancer treatment. The company's IMP3ACT platform differentiates it through AI/ML-enabled synthesis, but capital and clinical execution remain competitive constraints.
Industry Context
Salarius Pharmaceuticals, Inc. operates in Peptide-conjugate oncology therapeutics.
Key facts
Founded: 2014 · Headquarters: Houston, US · Revenue: $0 · Market cap: $0.48B